1 2 3 4 5 6
читать далее ... Сравнительное изучение эффективности профилактического применения нефракционированного и низкомолекулярного гепаринов при хирургическом лечении онкологических больных. Клин- геронтология, 2002. 8 (4), 11-17. 16. Ясиновский М.А.. Лещинский А.Ф., Баркаган З.С., Остапчук Н.А. Салицилаты. М.: Медицина, 1975, 232 с. 17. 20th World Congress of the International Union of angiology. New York, April 711,2002. 18. Buchanan М., Blister S. Individual variations in the effect ofASA clinically. Can. J. Cardiol., 1995, 11, 221-227. 19. Dieri R., Peyvandi F., Santagostino E. et al. The thrombogram in rare inherited coagulation disorders; its relation to clinical bleeding. Thromb. Haemost., 2002, 88, 576-582. 20. Gusu P., Kottke-Marchant К., Poggio E. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol., 2001, 88, 230235. 21. Homoncik M., Jilma В., Hergovich N. et al. Monitoring of aspirin (ASA) pharmacodinamics with platelet function analyzer PFA-100. Thromb. Haemost., 2000, 83, 316-321. 22. McKee S., Sane D., Deliazgyris E. Aspirin resistance in caidiovascular disease: A review of prevalence,mechanisms, and clinical significance. Thromb. Haemost., 2002, 88 (5), 711-715. 23. Mueller M., Salat A., Stangi et al. Variable platelet response to low-dose ASA. Thromb. Haemost., 1997, 78, 1003-1007. 24. Samama M., Bara L ,Walenga J. Comparative mechanism of action and pharmacokinetics of pentasaccharide and LMW heparins. 16th Intern. Congr. on Thrombosis. Porto, 2000, 99-102. 25. Sixth ACCP Consensus conference on Antithrombotic therapy. Chest, 2001, 119 (1, Suppi). 26. Thrombosis and Haemostasis Issues in Cancer. International Conference, Bergamo. Haemostasis, 2001, 31 (Suppl. 1), 1-110. 27. Zimmerman N., Kienzle P., Winter J. et al. Aspirin resistance after coronary artery bypass grafting. J. Thorac. Cardiovascular. Surg., 2001, 121, 982-984.Источник: Баркаган З.С. и др. Клиническая фармакология и терапия. 2005. №3. С.51-53